Recombinant canarypox virus vaccine co-expressing genes encoding the VP2 and VP5 outer capsid proteins of bluetongue virus induces high level protection in sheep

Josh D. Boone, Udeni B. Balasuriya, Kemal Karaca, Jean Christophe Audonnet, Jiansheng Yao, Ling He, Robert Nordgren, Federica Monaco, Giovanni Savini, Ian Gardner, Nigel J Maclachlan

Research output: Contribution to journalArticle

72 Citations (Scopus)

Abstract

We describe the development and preliminary characterization of a recombinant canarypox virus vectored vaccine for protective immunization of ruminants against bluetongue virus (BTV) infection. Sheep (n = 6) immunized with recombinant canarypox virus vector (BTV-CP) co-expressing synthetic genes encoding the two outer capsid proteins (VP2 and VP5) of BTV serotype 17 (BTV-17) developed high titers (40-160) of virus-specific neutralizing antibodies and were resistant to challenge with a field strain of BTV-17. In contrast, sheep (n = 5) immunized with a commercial recombinant canarypox virus vector expressing the E and preM genes of West Nile virus were seronegative to BTV and developed pyrexia, lymphopenia, and extended, high-titered viremias following challenge exposure to the field strain of BTV-17. These data confirm that the BTV-CP vaccine may be useful for the protective immunization of ruminants against bluetongue, and it may avoid the problems inherent to live-attenuated (LA) BTV vaccines.

Original languageEnglish (US)
Pages (from-to)672-678
Number of pages7
JournalVaccine
Volume25
Issue number4
DOIs
StatePublished - Jan 8 2007

Fingerprint

Canarypox virus
Bluetongue virus
Capsid Proteins
coat proteins
Sheep
Vaccines
vaccines
sheep
Genes
genes
Ruminants
Immunization
ruminants
Bluetongue
immunization
Synthetic Genes
West Nile virus
Lymphopenia
synthetic genes
Viremia

Keywords

  • Bluetongue
  • Canarypox virus
  • Sheep
  • Vaccine

ASJC Scopus subject areas

  • Immunology
  • Microbiology
  • Virology
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)

Cite this

Recombinant canarypox virus vaccine co-expressing genes encoding the VP2 and VP5 outer capsid proteins of bluetongue virus induces high level protection in sheep. / Boone, Josh D.; Balasuriya, Udeni B.; Karaca, Kemal; Audonnet, Jean Christophe; Yao, Jiansheng; He, Ling; Nordgren, Robert; Monaco, Federica; Savini, Giovanni; Gardner, Ian; Maclachlan, Nigel J.

In: Vaccine, Vol. 25, No. 4, 08.01.2007, p. 672-678.

Research output: Contribution to journalArticle

Boone, Josh D. ; Balasuriya, Udeni B. ; Karaca, Kemal ; Audonnet, Jean Christophe ; Yao, Jiansheng ; He, Ling ; Nordgren, Robert ; Monaco, Federica ; Savini, Giovanni ; Gardner, Ian ; Maclachlan, Nigel J. / Recombinant canarypox virus vaccine co-expressing genes encoding the VP2 and VP5 outer capsid proteins of bluetongue virus induces high level protection in sheep. In: Vaccine. 2007 ; Vol. 25, No. 4. pp. 672-678.
@article{9217c55da856410c9a57ac255d17283e,
title = "Recombinant canarypox virus vaccine co-expressing genes encoding the VP2 and VP5 outer capsid proteins of bluetongue virus induces high level protection in sheep",
abstract = "We describe the development and preliminary characterization of a recombinant canarypox virus vectored vaccine for protective immunization of ruminants against bluetongue virus (BTV) infection. Sheep (n = 6) immunized with recombinant canarypox virus vector (BTV-CP) co-expressing synthetic genes encoding the two outer capsid proteins (VP2 and VP5) of BTV serotype 17 (BTV-17) developed high titers (40-160) of virus-specific neutralizing antibodies and were resistant to challenge with a field strain of BTV-17. In contrast, sheep (n = 5) immunized with a commercial recombinant canarypox virus vector expressing the E and preM genes of West Nile virus were seronegative to BTV and developed pyrexia, lymphopenia, and extended, high-titered viremias following challenge exposure to the field strain of BTV-17. These data confirm that the BTV-CP vaccine may be useful for the protective immunization of ruminants against bluetongue, and it may avoid the problems inherent to live-attenuated (LA) BTV vaccines.",
keywords = "Bluetongue, Canarypox virus, Sheep, Vaccine",
author = "Boone, {Josh D.} and Balasuriya, {Udeni B.} and Kemal Karaca and Audonnet, {Jean Christophe} and Jiansheng Yao and Ling He and Robert Nordgren and Federica Monaco and Giovanni Savini and Ian Gardner and Maclachlan, {Nigel J}",
year = "2007",
month = "1",
day = "8",
doi = "10.1016/j.vaccine.2006.08.025",
language = "English (US)",
volume = "25",
pages = "672--678",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "4",

}

TY - JOUR

T1 - Recombinant canarypox virus vaccine co-expressing genes encoding the VP2 and VP5 outer capsid proteins of bluetongue virus induces high level protection in sheep

AU - Boone, Josh D.

AU - Balasuriya, Udeni B.

AU - Karaca, Kemal

AU - Audonnet, Jean Christophe

AU - Yao, Jiansheng

AU - He, Ling

AU - Nordgren, Robert

AU - Monaco, Federica

AU - Savini, Giovanni

AU - Gardner, Ian

AU - Maclachlan, Nigel J

PY - 2007/1/8

Y1 - 2007/1/8

N2 - We describe the development and preliminary characterization of a recombinant canarypox virus vectored vaccine for protective immunization of ruminants against bluetongue virus (BTV) infection. Sheep (n = 6) immunized with recombinant canarypox virus vector (BTV-CP) co-expressing synthetic genes encoding the two outer capsid proteins (VP2 and VP5) of BTV serotype 17 (BTV-17) developed high titers (40-160) of virus-specific neutralizing antibodies and were resistant to challenge with a field strain of BTV-17. In contrast, sheep (n = 5) immunized with a commercial recombinant canarypox virus vector expressing the E and preM genes of West Nile virus were seronegative to BTV and developed pyrexia, lymphopenia, and extended, high-titered viremias following challenge exposure to the field strain of BTV-17. These data confirm that the BTV-CP vaccine may be useful for the protective immunization of ruminants against bluetongue, and it may avoid the problems inherent to live-attenuated (LA) BTV vaccines.

AB - We describe the development and preliminary characterization of a recombinant canarypox virus vectored vaccine for protective immunization of ruminants against bluetongue virus (BTV) infection. Sheep (n = 6) immunized with recombinant canarypox virus vector (BTV-CP) co-expressing synthetic genes encoding the two outer capsid proteins (VP2 and VP5) of BTV serotype 17 (BTV-17) developed high titers (40-160) of virus-specific neutralizing antibodies and were resistant to challenge with a field strain of BTV-17. In contrast, sheep (n = 5) immunized with a commercial recombinant canarypox virus vector expressing the E and preM genes of West Nile virus were seronegative to BTV and developed pyrexia, lymphopenia, and extended, high-titered viremias following challenge exposure to the field strain of BTV-17. These data confirm that the BTV-CP vaccine may be useful for the protective immunization of ruminants against bluetongue, and it may avoid the problems inherent to live-attenuated (LA) BTV vaccines.

KW - Bluetongue

KW - Canarypox virus

KW - Sheep

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=33845344012&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845344012&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2006.08.025

DO - 10.1016/j.vaccine.2006.08.025

M3 - Article

C2 - 17059856

AN - SCOPUS:33845344012

VL - 25

SP - 672

EP - 678

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 4

ER -